# US 2025/0144085 A1 · Pharmaceutical composition for preventing or treating cancer comprising omeprazole browning matter

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144085 A1
- Document ID: US20250144085A1
- Status: Published application
- Kind: A1
- Application number: 18/694,723
- Filed: 2022-09-23
- Published: 2025-05-08
- Earliest claimed: 2021-09-23
- Assignees: New Cancer Cure-Bio Co., Ltd.
- Applicants: New Cancer Cure Bio Co., Ltd
- Inventors: Soo Youl KIM
- Web page: https://patentgrep.com/patent/US20250144085A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, and anticancer adjuvants, comprising omeprazole (KN510) browning substance. In the present invention, omeprazole browning substance (acid degradation substance) was prepared by treating conventional omeprazole with acid, and when the prepared omeprazole browning substance (acid degradation substance) was treated on a pancreatic cancer cell line, etc, it was confirmed that the anticancer effect was significantly increased compared to conventional omeprazole. Therefore, the omeprazole (KN510) browning substance (acid degradation substance) of the present invention can be utilized as a composition for preventing or treating cancer, or as an anticancer adjuvant.

## Claims

### Claim 1

A pharmaceutical composition for the prevention or treatment of cancer, comprising omeprazole browning substance (acid degradation substance) or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 2 (depends on 1)

The pharmaceutical composition for the prevention or treatment of cancer of claim 1, wherein the omeprazole browning substance (acid degradation substance) is an acid degradation substance with a pH in the range of 1 to 6.

### Claim 3 (depends on 1)

The pharmaceutical composition for the prevention or treatment of cancer of claim 1, wherein the omeprazole browning substance (acid degradation substance) is prepared by treating omeprazole with an acid or acidic solution having a pH ranging from 1 to 6.

### Claim 4 (depends on 3)

The pharmaceutical composition for the prevention or treatment of cancer of claim 3, wherein the acid or acidic solution having a pH in the range of 1 to 6 is hydrogen chloride (HCl), acetic acid, or lactic acid.

### Claim 5 (depends on 1)

The pharmaceutical composition for the prevention or treatment of cancer of claim 1, wherein the cancer is one or more cancers selected from the group consisting of colorectal cancer, lung cancer, gastric cancer, breast cancer, melanoma, prostate cancer, ovarian cancer, kidney cancer, pancreatic cancer, glioblastoma, and liver cancer.

### Claim 6 (depends on 1)

The pharmaceutical composition for the prevention or treatment of cancer of claim 1, wherein the composition further comprises an additional anticancer agent, and the anticancer agent is selected from the group consisting of one or more metabolic inhibitors selected from the group consisting of Irinotecan, fluorouracil, 5-FU), Paclitaxel, Gemcitabine, Cisplatin, Vermurafenib and pharmaceutically acceptable salts thereof; and/or one or more tumor immunosuppressants selected from the group consisting of Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab, and Durvalumab.

### Claim 7

An anticancer adjuvant comprising omeprazole browning substance (acid degradation substance) or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 8 (depends on 7)

The anticancer adjuvant of claim 7, wherein the omeprazole browning substance (acid degradation substance) is an acid degradation substance with a pH in the range of 1 to 6.

### Claim 9 (depends on 7)

The anticancer adjuvant of claim 7, wherein the omeprazole browning substance (acid degradation substance) is prepared by treating omeprazole with an acid or acidic solution having a pH ranging from 1 to 6.

### Claim 10 (depends on 7)

The anticancer adjuvant of claim 7, wherein the acid or acidic solution having a pH in the range of 1 to 6 is hydrogen chloride (HCl), acetic acid, or lactic acid.

### Claim 11 (depends on 7)

The anticancer adjuvant of claim 7, wherein the cancer is one or more cancers selected from the group consisting of colorectal cancer, lung cancer, gastric cancer, breast cancer, melanoma, prostate cancer, ovarian cancer, kidney cancer, pancreatic cancer, glioblastoma, and liver cancer.

### Claim 12 (depends on 7)

The anticancer adjuvant of claim 7, wherein the anticancer adjuvant further comprises an additional anticancer agent, and the anticancer agent is selected from the group consisting of one or more metabolic inhibitors selected from the group consisting of Irinotecan, fluorouracil, 5-FU), Paclitaxel, Gemcitabine, Cisplatin, Vermurafenib and pharmaceutically acceptable salts thereof; and/or one or more tumor immunosuppressants selected from the group consisting of Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab, and Durvalumab.

### Claim 13

A method for preventing or treating cancer, comprising administering omeprazole browning substance (acid degradation substance) or a pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof.
